Pharmacy Drugs
Recent Posts
- Malignant Brain Tumors: Chemotherapy Alone Is Just As Effective As Radiation / New Positive Prognostic Factor Found
- Positive Interim Data From Minnow Medical Peripheral Artery Disease Trial Presented At TCT 2009 Conference
- Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint In A Phase II Clinical Trial In Type 2 Diabetic Patients
- Largest Clinical Trial To Test Benefits Of Aspirin In Australia
- University Of Florida To Receive $29.5 Million In Recovery Act Funds To Begin Study Of Whether Exercise Prevents Disability In Older Adults
Random Posts
- New Scientific Data On ADHD Treatments Presented By Shire At National Psychiatric Scientific Meeting
- Depomed Reports Encouraging Results Of Its Phase I Trial For DM-1992 Program In Parkinson's Disease
- Gene Therapy And Stem Cells Save Limb
- Facet Biotech And Bristol-Myers Squibb Report Promising Phase I/II Interim Data For Elotuzumab In Patients With Relapsed Multiple Myeloma
- Sequel Systems Urges Hospital-Based And Managed Services Organizations To Adopt E-Prescribing Procedures
- FDA Device Chief Quits as Ethics Probe Targets CDER Director
- The Medicines Company's Full Analysis Of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patient Outcomes Following PCI
- RISPERDAL CONSTA (risperidone) Long-Acting Treatment May Improve Health Outcomes And Reduce Hospitalizations In Patients With Schizophrenia
- White Matter Changes May Predict Dementia Risk
- CombinatoRx Presents Full Data On Synavive Phase 2 Knee OA Trial At EULAR 2009
FDA Accepts Arno Therapeutics’ IND For AR-12 A PDK1 Inhibitor That Blocks The PI3K/Akt Pathway
Posted by: admin in Pharmacy Drugs on November 23rd, 2009
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that the U.S.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.